Answers are grounded in this paper and cite their sources.
SARS-CoV-2 (Severe Acute Respiratory Syndrome) is an etiologic agent of novel coronavirus disease (COVID-19), creating an alarming situation globally. Considering its sustained outbreak, the World Health Organization on 11th march 2020 has declared public health emergency around the world. Orf6 is a small accessory protein, encoded by the genome of SARS-CoV-2 and plays an important role in viral life cycle, pathogenesis and virulence. In the present study, 52,496 sequences of Orf6 reported from all over the world were compared to address structural variations in the protein. The results of our study showed a total of 779 mutations submitted in the month of March 2020 to 1st February 2021. Ten frequent mutations were found among the 779 mutations. Subsequently, the nature (deleterious or neutral) of mutations and protein modeling was conducted which revealed these frequent mutations considerably altered the structure of Orf6 protein. Further, physicochemical properties, antigenicity, allergenicity, toxicity and stability of Orf6 protein were estimated to demonstrate the stability of protein. Additionally, we identified 3 T-cell immune epitopes; their MHC restriction as well as MHC cluster analysis has also been performed which showed predicted epitopes can be a promising vaccine candidate to fight against COVID-19 infections.
No takes yet. Share an insight, caveat, or question.
Jha et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: